STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Rich Cockrell – Investor Relations Dolev Rafaeli – President and Chief Executive Officer Chris Lesovitz – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Thalmann Operator Greetings, and welcome to the STRATA Skin Sciences Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 13-3986004 (State ...

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Jones - IR Bob Moccia - CEO Chris Lesovitz - CFO Conference Call Participants Destiny Hance - Ladenburg Thalmann Operator Greetings. Welcome to STRATA Skin Sciences' 2Q 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is bein ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 13-3986004 (State or o ...

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Bob Moccia - Chief Executive Officer Chris Lesovitz - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to the STRATA Skin Sciences First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen only mode. A question-and-answer session will follow the formal presentation [Operator Instructions]. Pl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 13-3986004 (State or ...

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q4 2022 Earnings Conference Call March 31, 2023 8:30 AM ET Company Participants Bob Moccia - CEO Chris Lesovitz - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Hello, and welcome to the STRATA Skin Sciences Fourth Quarter 2022 and Full Year Earnings Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to [indiscernible]. Please go ahead. Unidentified Compa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11635 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 13-3986004 (State or Other Jurisdiction of (I.R.S. Employer incorporation or Organ ...

行业和公司概述: 1. 该公司是一家专注于皮肤科医疗设备的上市公司,主要产品是XTRAC 308纳米准分子激光系统 [1] 2. 公司在美国国内市场拥有约784台XTRAC设备,是该领域的主要参与者,与另一家竞争对手分享市场 [27] 3. 公司在韩国、日本等海外市场也有数百台XTRAC设备安装,是当地的行业标准 [15][16] 核心观点和论据: 1. 公司在2018年完成了财务重组,改善了资产负债表,为未来发展奠定了基础 [9] 2. 公司加大了对直接面向消费者(DTC)广告的投入,带动了新患者的增加,每年新增患者数量增长29% [10][11] 3. 公司通过"comeback"策略,将非生产性设备更换为新的生产性设备,提升了毛利率 [12] 4. 公司与私募股权支持的连锁皮肤科诊所合作,大幅增加了设备安装量 [13] 5. 公司在韩国和日本等海外市场推出了新的设备置换模式,未来将带来更多的经常性收入 [14][16] 6. 公司在技术方面也有所突破,推出了新一代XTRAC S3设备和多微剂量(MMD)技术,提升了治疗效果 [17][18] 其他重要内容: 1. 公司2018年全年净亏损400万美元,较2017年的2150万美元大幅改善 [28] 2. 公司2019年第三季度末现金余额超1600万美元,财务状况良好 [29] 3. 公司需要重新报告2017-2019年的财务数据,主要涉及一些非现金会计调整,但不影响基本业务 [21]-[25]